BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Next generation anti-androgen therapies such as enzalutamide and abiraterone have had a profound impact on the management of metastatic castration-resistant prostate cancer (mCRPC). However, mCRPC patients invariably develop resistance to these agents. Here, a series of clonal cell lines were develo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Cancer Res
Hauptverfasser: Asangani, Irfan A., Wilder-Romans, Kari, Dommeti, Vijaya L., Krishnamurthy, Pranathi M., Apel, Ingrid J., Escara-Wilke, June, Plymate, Stephen R., Navone, Nora M., Wang, Shaomeng, Feng, Felix Y., Chinnaiyan, Arul M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4834259/
https://ncbi.nlm.nih.gov/pubmed/26792867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-15-0472
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge